A-dec, Inc.
$1.8M 7,139 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Merz Pharmaceuticals, LLC
Merz Pharmaceuticals, LLC reported $1,799,715.78 across General Payments, Research, and Ownership to 7,100 physicians and teaching hospitals across 7,208 transactions.
- $1.8M Top quartile payer
- All-tracks total
- 7,208 Top quartile volume
- Transactions
- 7,100 Top quartile reach
- Recipients
- −$168.3K
- General Payments vs PY2023
Merz Pharmaceuticals, LLC reported $1,799,715.78 across all CMS Open Payments tracks (General + Research + Ownership) to 7,100 physicians and teaching hospitals in Program Year 2024 - ranking #476 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $919,545.00, averaging $253.48 per recipient.
How Merz Pharmaceuticals, LLC's $1.8M all-tracks total breaks down
Merz Pharmaceuticals, LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
63/100
Total payments
F
27/100
Transaction volume
D
62/100
Physician reach
D
64/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer merz-pharmaceuticals-llc Merz Pharmaceuticals, LLC
$1.8M · #476/1,925 · 0.0% industry · PY2024
- TOT $1.8M
- RANK #476
- SHARE 0.0%
- TXN 7,208
- RCP 7,100
- CAT 8
- GEN $919.5K
- ΔGEN −$168.3K
- TOP1 6.7%
- PY 2024
Volume peers
Nearest volume peer: A-dec, Inc. ($1.8M)
Merz Pharmaceuticals, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Merz Pharmaceuticals, LLC's CMS-reported General Payments decreased by $168.3K (−15.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: MERZ PHARMACEUTICALS, LLCPY2023: MERZ PHARMACEUTICALS, LLCPY2024: Merz Pharmaceuticals, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,087,826.16
- PY2024
- $919,545.00
What the Data Shows for Merz Pharmaceuticals, LLC
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Merz Pharmaceuticals, LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Consulting Fee" leads the 8-category general-payment breakdown below at $216.0K (23.5% of General Payments, 78 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Merz Pharmaceuticals, LLC made 8 types of general payments. "Consulting Fee" is the largest category at $216.0K, 23.5% of General Payments.
Merz Pharmaceuticals, LLC reports 8 general-payment categories - the top three are Consulting Fee (23.5%), Food and Beverage (22.8%), and Compensation for Services Other Than Consulting (15.4%). The remaining 5 categories make up 38.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Merz Pharmaceuticals, LLC files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Merz Pharmaceuticals, LLC divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $216.0K | 78 | 23.5% |
| Food and Beverage | $209.3K | 6,521 | 22.8% |
| Compensation for Services Other Than Consulting | $141.9K | 64 | 15.4% |
| Travel and Lodging | $119.8K | 254 | 13.0% |
| Grant | $105.2K | 17 | 11.4% |
| Space Rental or Facility Fees | $71.8K | 20 | 7.8% |
| Debt Forgiveness | $48.9K | 42 | 5.3% |
| Education | $6.6K | 104 | 0.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $196,523.65 (21.4%) of $919,545.00 in this company's General Payments records across 3,443 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Merz Pharmaceuticals, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Gerard Francisco
$61,373.02 across 45 reported transactions
- 2
Todd Stitik
$42,191.95 across 56 reported transactions
- 3
Monica Verduzco-Gutierrez
$36,229.08 across 23 reported transactions
- 4
Vanderbilt University Medical Center
$31,850.00 across 4 reported transactions
- 5
University Of Washington Med Ctr
$24,879.60 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Merz Pharmaceuticals, LLC ranks #476 of 1,925 by total payments (top 25% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,612 of 1,838 by HHI (bottom 12% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- TG Therapeutics, Inc. : $4.7M total payments, HHI 163
- Johnson & Johnson Surgical Vision, Inc. : $1.6M total payments, HHI 163
- Fortis Surgical, LLC : $45.6K total payments, HHI 163
- Deciphera Pharmaceuticals Inc. : $602.7K total payments, HHI 162
- Radius Health, Inc. : $792.8K total payments, HHI 162
- Kuros Biosciences USA, Inc : $711.3K total payments, HHI 162
- Merz Pharmaceuticals, LLC (this company) : $919.5K total payments, HHI 162
- Vanda Pharmaceuticals Inc. : $4.6M total payments, HHI 160
- CeQur Corporation : $420.1K total payments, HHI 160
- Kiniksa Pharmaceuticals International, plc : $1.7M total payments, HHI 159
- Lundbeck LLC : $4.1M total payments, HHI 159
- Foundation Fusion Solutions, LLC : $106.1K total payments, HHI 157
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Merz Pharmaceuticals, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Merz Pharmaceuticals, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Merz Pharmaceuticals, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Dendreon Pharmaceuticals LLC
$1.8M 10,334 recipients
Compare payment profiles
Merck Healthcare KGaA
$1.8M 36 recipients
Compare payment profiles
MDD US Operations, LLC
$1.8M 11,285 recipients
Compare payment profiles
Preceptis Medical, Inc.
$1.8M 109 recipients
Compare payment profiles
XVIVO Perfusion Inc.
$1.8M 141 recipients
Compare payment profiles
Put this to use
Merz Pharmaceuticals, LLC ranks #476 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Merz Pharmaceuticals, LLC sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Merz Pharmaceuticals, LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.